Daily Newsletter

20 November 2023

Daily Newsletter

20 November 2023

Regent acquires majority ownership in Oregon Surgical Institute

The partnership started in 2016, leading to the creation of the first ASC in the northwest US to focus on complex cases.

November 17 2023

Regent Surgical Health has expanded its joint venture alliance with Oregon Surgical Institute (OSI), acquiring majority ownership in the latter.

This investment highlights the growing value and access to surgical care that is being created by physician-led ambulatory surgery centres (ASCs).

The partnership started in 2016, leading to the creation of the northwest US’ first ASC to focus on complex cases, mainly spinal issues and total joint replacement.

Regent COO Jeff Andrews said: “Regent’s increased investment will further enable the world-class clinical team at Oregon Surgical Institute to focus on the delivery of industry-leading care while also excelling the orthopaedic and total joint space in general.

“Our evolved partnership was made possible by the trust OSI’s leadership team has placed in us, and this will bolster both value and access by strengthening OSI’s position as a home for the growing list of procedures being delivered through ambulatory surgical centres nationally.”

OSI is an outpatient surgery centre specialising in complex cases.

With Regent's support, it is claimed to have gained the capacity to meet the increasing demand for surgical care outside of the traditional hospital setting, achieving high scores in quality, safety, and team member engagement.

OSI member of the governing board Christopher Nanson said: “As financial challenges continue to intensify for hospitals, opportunities are multiplying for leading providers like Oregon Surgical Institute to perform a growing variety of procedures while serving a wider spectrum of patient acuity.

“Regent’s partnership model ensures our physician leaders can forecast and leverage changing market trends while also maintaining the level of control over processes and clinical protocols to drive patient and employee satisfaction.

“They are collaborative listeners who have been critical in advancing our vision.”

Regent is a national platform for ASCs and operates in over 15 states, emphasising health system joint venture partnerships.

Is it time for the healthcare sector to fully embrace the benefits of digitalization and AI?

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close